Rachel Blank didn’t have to imagine her first customer. TechCrunch reports she was diagnosed with polycystic ovary syndrome at 21 and found nowhere to go. “There weren’t a lot of places for me to go, because the concept of a specialist for my condition didn’t exist,” she said. Allara, the company she founded to fill that gap, raised $30 million in October 2026, per AlleyWatch’s funding report.
| At a glance | |
|---|---|
| Founder and CEO | Rachel Blank |
| Company | Allara, founded 2020 |
| What it does | Insurance-covered telehealth care for hormonal, metabolic and reproductive conditions |
| Conditions | PCOS, endometriosis, hypothyroidism and others |
| Latest round | $30 million, reported October 13, 2026 |
| Investors | Index Ventures, GV, Camino Partners, Foreground, Family Fund |
| Total equity funding | $75 million, per AlleyWatch |
| Growth on record | Revenue up 4x in 2024, per TechCrunch |
A strategist with a personal reason
Blank grew up with an OB-GYN father, per TechCrunch, and before Allara she was director of strategy at Ro, the online clinic. That’s a useful background for this business: she had watched a direct-to-consumer health company scale, and she had been the patient who couldn’t find the right doctor.
Allara treats women with chronic hormonal conditions through an online care team. The average patient is 30, per TechCrunch, which notes that rivals such as Tia, Midi Health and Gennev focus more on fertility or menopause, while Allara concentrates on long-term conditions that often show up before patients are ready to have children.
From subscription to insurance
The biggest change in the model has been who pays. Allara started as an out-of-pocket subscription. By January 2025 it was partnered with Aetna, Blue Cross Blue Shield, Cigna, Humana and UnitedHealthcare, with services covered by insurance in 10 states, and Blank said she would use the Series B to expand coverage nationwide. Revenue grew 4x in 2024.
Investors have backed that shift round after round.
Index Ventures led the $26 million Series B 14 months after the $10 million Series A, and came back for the October 2026 round alongside GV. Index partner Martin Mignot explained the bet in 2025: “If you have a relationship with your care providers since you are 20 or 25, it is very natural to stay over time.” AlleyWatch describes the company now as “a telehealth platform that delivers insurance-covered care for women with hormonal, metabolic, and reproductive conditions.” No valuation has been reported for any round.
Part of a wider wave
Allara’s raise was announced the same day as another women’s health round. Dr. Stacy Sims’s Collective X Health raised $3.2 million to build a research base on women’s physiology, and Val Emanuel’s Rif Care grew out of her own hormone crisis, the same kind of first-hand frustration that started Allara. The difference is scale: Blank’s company now has $75 million in reported equity behind it, and insurers paying for its care.
Allara hasn’t published 2025 or 2026 revenue, patient numbers or its current insurance footprint, so we don’t estimate them.
Sources: AlleyWatch (October 13, 2026), TechCrunch (January 24, 2025). Last checked October 28, 2026.
Frequently asked questions
Who founded Allara?
Rachel Blank, who is also its CEO. TechCrunch reports she was diagnosed with PCOS at 21, grew up with an OB-GYN father, and was a director of strategy at Ro before founding Allara. AlleyWatch lists its founding year as 2020.
What does Allara treat?
Hormonal, metabolic and reproductive conditions in women, including PCOS, endometriosis and hypothyroidism, through an online care team. TechCrunch reports the average patient is 30.
Does Allara take insurance?
Yes. It began as an out-of-pocket subscription but, per TechCrunch in January 2025, partners with Aetna, Blue Cross Blue Shield, Cigna, Humana and UnitedHealthcare, with services covered by insurance in 10 states at that time.
How much has Allara raised?
AlleyWatch reports $75 million in total equity funding after a $30 million round in October 2026. Earlier rounds included a $10 million Series A and a $26 million Series B led by Index Ventures in January 2025.